Resilient Together for Dementia
The proposed study will establish the feasibility, acceptability and credibility of a novel
live video dyadic resiliency intervention, Resilient Together for Dementia (RT-D), aimed at
preventing chronic emotional distress and preserving quality of life among dyads a...
Age: 65 years - 66+
Gender: All
Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease
The purpose of this study is to assess the effectiveness, safety, and tolerability of
BMS-986446 an Anti-MTBR Tau Monoclonal Antibody in participants with Early Alzheimer's
Disease.
Age: 50 - 80 years
Gender: All
Methodology Issues in a Tailored Light Treatment for Persons With Dementia - Aim 2
Aim 2 will investigate the effect of 3 different light exposure lengths on sleep, mood and
agitation in persons with Alzheimer's disease. Participants will be randomly assigned to one
of three conditions of light exposure: 1) 2-h morning light exposure; 2) 4-h morni...
Age: 65 years - 66+
Gender: All
7T MRI for Light Therapy in Patients With Mild Cognitive Impairment and Mild AD
The purpose of this research study is to investigate the effect of a light treatment on
sleep, memory and brain function. In people with mild cognitive impairment (MCI) and
Alzheimer's disease, sleep-wake disturbance is evident in up to 60% of patients. This can be
...
Age: 50 - 85 years
Gender: All
A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease
This is a multicenter randomized, double-blind, placebo-controlled Phase 2 study designed
to evaluate the efficacy, safety, and tolerability of two doses of CT1812 compared to
placebo in participants diagnosed with early Alzheimer's disease.
Age: 50 - 85 years
Gender: All
Phase 2 - Rhythmic Light Therapy for Alzheimer's Disease Patients
Participants will randomly be placed into one of four groups and experience one of the four
following conditions: (1) a placebo light that provides a 40 hertz (Hz) flicker (rhythmic
light [RL]); (2) a placebo light with a random flicker (placebo condition for rhythm...
Age: 55 years - 66+
Gender: All
Rhythmic Light Therapy for Alzheimer's Disease Patients
The investigator will investigate how light delivering 40 hertz (Hz) affects subjective sleep
and cognition in a controlled laboratory study. A lab study will allow the collection of
electroencephalogram (EEG) data, perform cognitive tests, and observe the response ...
Age: 55 years - 66+
Gender: All
Music Therapy Experiences in Patients With Mild Cognitive Impairment (MCI) and Alzheimer's Disease (AD)
This study compares different music therapy (MT) experiences and their impact on memory and
language in patients with Alzheimer's disease and Mild Cognitive Impairment.
The 12-month study will assess the role of common experiences involving familiar music and
ot...
Age: 55 years - 66+
Gender: All
AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid
The primary purpose of this study is to determine whether treatment with lecanemab is
superior to placebo on change from baseline of the Preclinical Alzheimer Cognitive
Composite 5 (PACC5) at 216 weeks of treatment (A45 Trial) and to determine whether
treatment with ...
Age: 55 - 80 years
Gender: All
The Long-term Impact of a Light Intervention on Sleep and Cognition in Mild Cognitive Impairment
To investigate the impact of a long-term light treatment intervention on sleep physiology and
memory in mild cognitively impaired and mild Alzheimer's disease patients living at home. The
goal is also to measure the impact of the lighting intervention on caregivers'...
Age: 50 years - 66+
Gender: All
Light, Metabolic Syndrome and Alzheimer's Disease - Aim 2
To test the long term effect of a light treatment on cognition, sleep and metabolism in
patients with Mild cognitive impairment (MCI) or mild Alzheimer's disease or related dementia
(ADRD).
Age: 55 years - 66+
Gender: All
Light and the Effect on Metabolic Syndrome and Alzheimer's Disease
This study's main hypothesis is that a delivering a tailored lighting intervention (TLI) will
provide a successful means for promoting circadian entrainment and treating metabolic disease
and inflammation in patients with mild cognitive impairment (MCI) and Alzheime...
Age: 55 years - 66+
Gender: All
An Efficacy and Safety Study of JNJ-54861911 in Participants Who Are Asymptomatic at Risk for Developing Alzheimer's Dementia
The purpose of this study is to evaluate whether treatment with JNJ-54861911 slows cognitive
decline compared with placebo treatment, as measured by a composite cognitive measure, the
Preclinical Alzheimer Cognitive Composite (PACC), in amyloid-positive participants w...
Age: 60 - 85 years
Gender: All